Drugmaker Indivior seeks shareholder approval to move primary listing from London to New York Stock market Opioid dependence treatment maker Indivior has confirmed a plan to move its primary stock market listing from London to New York this summer in yet another blow to the capital's beleaguered bourse.
Indivior plans primary US listing in another hit to London’s flagging equity market Not another one While the firm said it would look to maintain a secondary listing in the UK, the decision to shift its primary listing marks a big change for the company.
Opioid treatment firm Indivior upgrades outlook and shares take off Drug addiction treatment firm Indivior upgrades outlook and shares take off Drug addiction treatment firm Indivior upgrades outlook and shares take off
Indivior swings to $42m loss as opioid treatment prices fall February 13, 2020 Drugmaker Indivior saw its shares slump nearly 20 per cent this morning after the firm booked a loss for the fourth quarter on the back of falling prices for its flagship opioid treatment. The figures Indivior, which is best known for its opioid addiction products, swung to a $42m (£32.4m) loss for the last three [...]
Indivior shares soar as Suboxone posts slower market share decline July 11, 2019 Indivior soared on the markets this morning as it raised full-year guidance after its Suboxone lost less market share than was expected. Shares had jumped nearly 40 per cent by around 9am, as the company raised net revenue guidance to between $670m (£495m) and $720m. It had previously forecast revenues of $525m to $575m. They [...]
Best 25 stocks in the last tax year April 15, 2019 | City Talk By Graeme Evans from interactive investor. The FTSE 100 outperformed mid-caps last tax year, but the top FTSE 350 performers might surprise you. Take a look at the financial year ended on the 5th April, with the 25 top performing stocks in the FTSE 350 all producing gains of 40 per cent or more over the [...]
Indivior share price crashes 70 per cent after allegations of fraudulent drug marketing scheme April 10, 2019 Shares in FTSE 250-listed drug company Indivior crashed 70 per cent this morning after it was hit with a US indictment containing 28 felony counts last night. Its shares were down 70 per cent at 31p this morning. Reckitt Benckiser, its former parent company, saw its shares slide six per cent to 6,014p. Read more: Indivior [...]
Big pharma: Indivior launches generic version of own drug to beat copycats February 20, 2019 British drugs firm Indivior has launched a copycat version of its opioid addiction drug Suboxone in the US, shortly after a court allowed rivals to market generic versions of it. Read more: Indivior share price plunges on US court defeat which could hit sales hard The firm's shares were up 1.8 per cent this afternoon. [...]
Indivior boosts profits but warns of US market uncertainty for key drugs February 14, 2019 Ftse-250 pharmaceuticals company Indivior said today its operating profit increased 51 per cent to $292m (£228m) in 2018. The company said revenue fell eight per cent to $1.005bn, however it said this lower revenue was partially offset by a reduction in operating costs. Indivior did not give financial forecasts for the 2019 financial year due [...]
Indivior share price dives on US court defeat which could hit sales hard February 5, 2019 Pharmaceutical company Indivior’s share price crashed 17 per cent this morning after a US court ruling opened the way for rivals to sell a generic version of its opioid addiction treatment drug in the US. Shares fell from 113p last night to 93p this morning following the decision. The US Court of Appeals for the Federal [...]